Emicizumab is efficacious in people with hemophilia A with comorbidities aged ≥50 years: analysis of 4 phase III trials
The treatment of older people with hemophilia A (HA) can be complicated by comorbidities. This post hoc analysis evaluates the efficacy and safety of emicizumab in people with HA aged ≥50 years with cardiovascular (CV) risk factors or HIV and/or hepatitis C virus (HCV) infection. The HAVEN 1 (NCT026...
Saved in:
Published in | Research and practice in thrombosis and haemostasis Vol. 8; no. 3; p. 102405 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.03.2024
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!